Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of amitinib in newly diagnosed unresectable stage III EGFR-mutant non-small cell lung cancer
ChiCTR2000033950Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amitinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Objective response rate and Major pathologic response. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
amitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000033950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033950.